Stay updated on SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.

Latest updates to the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedMinor layout and formatting updates are visible; core study details such as title, criteria, design, and outcomes appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedAdded a government funding notice and an updated software version (v3.2.0), removing the old v3.1.0; this primarily updates the page’s operating status guidance and versioning.SummaryDifference5%

- Check49 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, with the addition of the new revision tag and removal of the old one.SummaryDifference0.3%

- Check63 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' link has been removed.SummaryDifference0.3%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%

- Check77 days agoChange DetectedThe page has undergone significant updates, including the addition of a facility name and specific location details, as well as the introduction of new medical terms related to skin and connective tissue diseases. Notably, the revision number has been updated to v3.0.0.SummaryDifference3%

Stay in the know with updates to SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SENSITIZE: 4SC-202 + Pembrolizumab Clinical Trial page.